معرفی
Mehdi Mirzaei is an Honorary Associate Professor at Macquarie Medical School, Macquarie University. His research focuses on neurodegenerative diseases, particularly Alzheimer's and glaucoma, with emphasis on proteomics and neuroprotective mechanisms. He has been actively involved in projects such as 'Modified Serpin as a Dual Function Therapeutic Agent in Glaucoma' (2023–2027) and 'Retinoid X Receptors and Rexinoids: Harnessing Neuroprotective Effects in Glaucoma' (2020–2023). His work integrates molecular biology, protein folding studies, and translational medicine to address retinal and brain pathologies.
Research Interests: Proteomics, neurodegeneration, glaucoma pathophysiology, retinal ganglion cell protection, amyloid and tau protein dynamics, and neuroinflammation. His recent studies explore therapeutic targets like RXR agonists and neuroserpin gene therapy to mitigate neurodegenerative processes.
Publications: Over 180 research outputs since 2009, with recent focus on retinal Alzheimer’s biomarkers, tau modulation in glaucoma, and protein folding mechanisms in neurodegeneration. Key themes include neuroprotective signaling pathways (e.g., PI3K/Akt, BDNF), immunomodulation, and extracellular vesicle-based therapies.
Grants & Projects: Leads or collaborates on 14 projects, including biomolecular discovery initiatives and clinical trials targeting glaucoma and Alzheimer’s. Active in international collaborations, such as the Biomolecular Discovery and Design Research Centre (2017–present).
Labs & Teams: Engaged in interdisciplinary teams at Macquarie Medical School, focusing on translational proteomics and neurodegenerative disease modeling. Collaborates with institutions globally on retinal and brain pathology studies.
